Has Omar Ibrahim, MD received payments from drug or device companies?

Yes. Drug and device makers reported $139,402 in general payments to Omar Ibrahim, MD across 269 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Omar Ibrahim, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Omar Ibrahim, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Omar Ibrahim, MD

Pulmonary Disease · Farmington, CTNPI 1487853941

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $101,117 of the $139,402 with a category attached, or 72.5%. Johnson & Johnson accounts for 66.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $38,276 and has fallen 60.2% since, to $15,236 in 2025. Among pulmonary disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$139,402in general payments, 2019–2025

Across 269 payments — averaging $518.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$92K
Medical Device Business Services, Inc.$21K
Ethicon Endo-surgery Inc.$16K
Intuitive Surgical$5K
Noah Medical Corporation$2K
Pulmonx Corporation$1K
plus $2K from 11 others

$149,118in research payments, 2019–2025

Across 14 payments — averaging $10,651 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Johnson & Johnson$63K
Janssen Research & Development, LLC$37K
Ethicon Endo-surgery Inc.$34K
Optellum Ltd$16K

What the payments were for

Consulting fees$101,11773%
Speaking & faculty fees$5000%
Travel & lodging$26,79219%
Food & beverage$8,4936%
Education$2,5002%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	173	$92,146
Medical Device Business Services, Inc.	37	$21,200
Ethicon Endo-surgery Inc.	8	$16,139
Intuitive Surgical	14	$4,728
Noah Medical Corporation	7	$2,133
Pulmonx Corporation	5	$1,169
Galvanize Therapeutics, Inc	6	$500
Pinnacle Biologics, Inc	4	$360
Covidien LP	5	$236
Boston Scientific	3	$208
Merz North America, Inc.	1	$151
Medtronic	1	$143
Janssen Research & Development, LLC	1	$113
Lexington Medical, Inc.	1	$95
AbbVie	1	$31
Pfizer	1	$26
Gilead	1	$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$139,402 in reported general payments places this provider in the 95th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut →

Medicare billing

Part B allowed, 2024

$96,158

Medicare patients

324

Services billed

1,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	66	$60,847
Breo ElliptaFluticasone/Vilanterol	60	$29,744
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	35	$20,744
Incruse ElliptaUmeclidinium Bromide	14	$6,062
Albuterol Sulfate HfaAlbuterol Sulfate	88	$2,401
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate	16	$1,829
Fluticasone-SalmeterolFluticasone Propion/Salmeterol	12	$1,421
Ventolin HfaAlbuterol Sulfate	11	$608
Wixela InhubFluticasone Propion/Salmeterol	11	$501
Montelukast Sodium	24	$270
Fluticasone Propionate	14	$258
Prednisone	20	$48

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Farmington

Mark MeterskyFarmington$88K
Nausherwan BurkiFarmington$9K
Geoffrey ChuppNew Haven$1.2M
Tapas BandyopadhyayWest Hartford$483K
Raj ParikhHartford$386K
Patrick TroyHartford$385K
Michael ImevboreNew Haven$323K
Jeffrey NascimentoHartford$213K
Thinesh DahanayakeNorwich$192K
Naftali KaminskiNew Haven$180K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →